Scarica l'app Stockscreener
0.9679
12.55%
0.1079
Precedente Chiudi:
$0.86
Aprire:
$0.93
Volume 24 ore:
2.95M
Relative Volume:
7.32
Capitalizzazione di mercato:
$22.70M
Reddito:
$7.10M
Utile/perdita netta:
$-31.59M
Rapporto P/E:
-0.3781
EPS:
-2.56
Flusso di cassa netto:
$-26.75M
1 W Prestazione:
+10.62%
1M Prestazione:
+5.87%
6M Prestazione:
-48.52%
1 anno Prestazione:
-60.81%
Intervallo 1D:
$0.9172
$1.20
Intervallo di 1 settimana:
$0.75
$1.20
Portata 52W:
$0.68
$5.65
Palatin Technologies Inc. Stock (PTN) Company Profile
Nome
Palatin Technologies Inc.
Settore
Industria
Telefono
609-495-2200
Indirizzo
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Confronta PTN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
0.9679 | 22.70M | 7.10M | -31.59M | -26.75M | -2.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2015-06-05 | Reiterato | Canaccord Genuity | Buy |
| 2015-01-12 | Reiterato | ROTH Capital | Buy |
| 2012-05-23 | Iniziato | Noble Financial | Buy |
| 2007-01-23 | Iniziato | Next Generation | Buy |
Palatin Technologies Inc. Borsa (PTN) Ultime notizie
Palatin Technologies (NYSEAMERICAN:PTN) Earns “Buy” Rating from HC Wainwright - Defense World
Palatin reports positive Phase 2b results in diabetic nephropathy - Yahoo Finance
First Patient Dosed in Phase 2 Clinical Study of Palatin's Breme - GuruFocus.com
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy - PR Newswire
Palatin Technologies announces warrant exercise for ~$3.4M gross proceeds - MSN
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds - The Eastern Progress Online
Palatin Technologies Secures $3.4M Through Strategic Warrant Exercise Deal, Issues New Warrants - StockTitan
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results - The Eastern Progress Online
Palatin Technologies (BUE:PTN) Financial Strength : 4 (As of Sep. 2024) - GuruFocus.com
Thinking about buying stock in MedAvail Holdings, Trio-Tech Inte - GuruFocus.com
PTN (Palatin Technologies) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
PTN (Palatin Technologies) COGS-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
Palatin Technologies stock stays Buy rated after completing Phase 2 enrollment in UC trial - Investing.com UK
Palatin Announces Completion of Patient Enrollment in Phase 2 St - GuruFocus.com
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis – Company AnnouncementFT.com - Financial Times
Palatin Completes Phase 2 Enrollment for Novel Ulcerative Colitis Pill, Data Due Q1 2025 - StockTitan
Palatin Technologies (FRA:PTN) Retained Earnings : €-405.08 Mil (As of Sep. 2024) - GuruFocus.com
Palatin Technologies (FRA:PTN) Graham Number : €N/A (As of Sep. 2024) - GuruFocus.com
Palatin Technologies (FRA:PTN) Float Percentage Of Total Sh - GuruFocus.com
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleco - GuruFocus.com
Palatin Technologies, Inc. (AMEX:PTN) Q1 2025 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc (PTN) Quarterly 10-Q Report - Quartzy
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Challenges - GuruFocus.com
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... - Yahoo Finance
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... By GuruFocus - Investing.com Canada
Palatin Technologies Shifts Focus to Obesity Treatments - TipRanks
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results - The Malaysian Reserve
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financi - GuruFocus.com
Indo-Asian News Service - IANS India Pvt Ltd
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 - BioSpace
Palatin Technologies Sets Q1 2025 Earnings Release for November 14 | PTN Stock News - StockTitan
Palatin Technologies (BUE:PTN) 9-Day RSI : N/A (As of Nov. 06, 2024) - GuruFocus.com
Palatin Technologies (BUE:PTN) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 - PR Newswire
HC Wainwright Reaffirms Buy Rating for Palatin Technologies (NYSEAMERICAN:PTN) - Defense World
Palatin Receives Notice of Non-Compliance from NYSE American - GuruFocus.com
Palatin Technologies, Inc. Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity - Marketscreener.com
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity - StockTitan
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones - GuruFocus.com
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium - BioSpace
PTNPalatin Technologies, Inc. Latest Stock News & Market Updates - StockTitan
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium - BioSpace
Palatin Presents Foundational Data on Novel and Highly Selective - GuruFocus.com
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium – Company AnnouncementFT.com - Financial Times
Dry Eye Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Palatin Technologies, Novaliq, mc2 therapeutics - The Globe and Mail
Palatin faces NYSE American non-compliance notice By Investing.com - Investing.com Australia
Palatin faces NYSE American non-compliance notice - Investing.com
Palatin Technologies (NYSEAMERICAN:PTN) Issues Quarterly Earnings Results - Defense World
Palatin Technologies, Inc. (AMEX:PTN) Q4 2024 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc. (PTN) is a good investment, but the stock may be undervalued - US Post News
Earnings call: Palatin highlights pipeline progress, asset sale in FY 2024 By Investing.com - Investing.com South Africa
Palatin Technologies Inc. Azioni (PTN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):